Daily Respiratory Research Analysis
Analyzed 196 papers and selected 3 impactful papers.
Summary
Three impactful studies advanced respiratory medicine today: targeted next-generation sequencing (tNGS) in Eswatini uncovered rifampicin I491F “diagnostic escape” and widespread bedaquiline resistance missed by routine TB tests; a high-performing clinical score distinguished PVOD/PCH from PAH with AUC 0.97 to guide safer therapy and transplant referral; and a multi-center RCT found remote monitoring after sepsis/lower respiratory infection did not improve days at home—and was worse in older adults—prompting reassessment of post-discharge digital care.
Research Themes
- Genomic diagnostics to close gaps in drug-resistant tuberculosis detection
- Risk stratification and early identification in pulmonary vascular disease
- Real-world evaluation and de-implementation of digital health monitoring post-acute infection
Selected Articles
1. Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.
Programmatic tNGS uncovered widespread rpoB I491F-mediated rifampicin resistance and Rv0678-associated bedaquiline resistance missed by standard tests. Over half of patients with detailed clinical data had their regimens changed based on tNGS, achieving high treatment success.
Impact: This implementation study reveals a major diagnostic blind spot and directly informs therapy in high-burden settings, challenging reliance on standard assays and the universality of current BPaLM regimens.
Clinical Implications: Adopt tNGS where rpoB I491F is prevalent to avoid false rifampicin susceptibility; systematically screen for Rv0678-mediated bedaquiline resistance; tailor regimens beyond BPaLM when genotypic resistance is detected; update diagnostic algorithms and resistance classifications.
Key Findings
- tNGS detected rifampicin resistance in 159/234 strains; 64% (101/159) carried rpoB I491F missed by routine tests.
- Bedaquiline resistance (Rv0678 mutations) was present in 87 strains—55% of RR and 85% of rpoB I491F strains.
- Routine diagnostics substantially under-classified resistance, especially in INH-R/RIF-S reports.
- tNGS led to regimen changes in 53% (31/59) with detailed follow-up; treatment success reached 88%.
Methodological Strengths
- Nationwide programmatic implementation with comprehensive genotypic profiling (tNGS) in a high-burden setting
- Actionable linkage to care: treatment changes and outcome tracking in a clinical subset
Limitations
- Observational design with detailed outcomes available for a subset (59/234), introducing potential selection bias
- Cost, infrastructure, and turnaround considerations for scaling tNGS in resource-limited settings
Future Directions: Prospective implementation-effectiveness evaluations, cost-effectiveness analyses, and integration of tNGS-triggered adaptive regimens in national TB programs; refine global resistance classifications incorporating rpoB I491F and Rv0678.
In Eswatini, multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains harbouring the rifampicin-resistance (RR) rpoB I491F mutation are missed by routine diagnostics, including GeneXpert MTB/RIF Ultra (Xpert Ultra), line probe assays (LPA), and mycobacterium growth indicator tube (MGIT) phenotypic drug susceptibility testing (pDST). To address this diagnostic gap, Eswatini introduced targeted next-generation sequencing (tNGS) in 2019. We analysed 234 patient samples enrolled from June 2021 to December 2024 with isoniazid and/or rifampicin resistance detected by routine diagnostics, or suspected treatment failure, and obtained detailed clinical and outcome data from 59 patients. tNGS detected RR in 159 strains, of which 101 (64%) carried the rpoB I491F mutation. Bedaquiline (BDQ) resistance, conferred by Rv0678 mutations, was identified in 87 strains, rendering 55% (87/159) of RR and 85% (86/101) of rpoB I491F strains genotypically BDQ-resistant. Routine tests substantially under-classified resistance, particularly in strains reported as isoniazid-resistant and rifampicin-susceptible. tNGS-informed treatment changes occurred in 53% (31/59) of patients, with 88% (52/59) treatment success. tNGS is therefore an essential tool to detect rpoB I491F "diagnostic escape" strains with additional BDQ resistance, and underscores the urgent need to reconsider current BPaLM regimens and global drug-resistance classifications.
2. Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement.
A parsimonious PVOD/PCH likelihood score using DLCO, exertional desaturation, PaO2, sex, smoking, and characteristic CT signs discriminated PVOD/PCH from PAH with AUC 0.97 across three transplant-eligible cohorts, maintaining performance with missing data.
Impact: Early identification of PVOD/PCH can prevent harmful vasodilator titration and accelerate transplant referral, addressing a critical mortality gap in pulmonary vascular disease management.
Clinical Implications: Use the score at incident PAH evaluation to flag PVOD/PCH and adjust therapy (avoid aggressive PAH vasodilators), intensify oxygen therapy and transplant evaluation, and tailor imaging and genetic testing workflows.
Key Findings
- Developed a PVOD/PCH likelihood score incorporating DLCO, 6MW desaturation, PaO2, sex, smoking, CT septal line thickening, and CT lymphadenopathy.
- Validated across three transplant-eligible cohorts (n=97 total) with histopathology confirmation; AUC 0.97 (95% CI 0.93–1.00).
- Score retained discrimination with missing variable data, supporting real-world applicability.
Methodological Strengths
- Multinational validation against histopathology-confirmed PVOD/PCH cases
- Robust discrimination with parsimonious variables and resilience to missing data
Limitations
- Retrospective design with a relatively small number of PVOD/PCH cases (n=37)
- Derivation based on pooled literature may introduce spectrum or publication bias
Future Directions: Prospective validation, integration into diagnostic pathways at PAH centers, and assessment of impact on treatment decisions, safety (pulmonary edema), and time-to-transplant outcomes.
RATIONALE: While therapeutic advances have improved survival in Group 1 Pulmonary Arterial Hypertension (PAH), patients with Group 1.5 "PAH with features of venous/capillary involvement" (formerly Pulmonary Veno-Occlusive Disease or Pulmonary Capillary Hemangiomatosis, now collectively termed PVOD/PCH) remain underrecognized, develop serious complications from usual PAH therapy titrations, and suffer high mortality awaiting necessary lung transplant. Identifying PVOD/PCH early before therapy initiation could aid management and expedite transplant referral. OBJECTIVE: We aimed to develop a likelihood score distinguishing PVOD/PCH from other forms of PAH using clinical variables. METHODS: Due to low PVOD/PCH prevalence and no dedicated registries, we leveraged published case control/series studies to assess the ability of several clinical variables to discriminate PVOD/PCH from PAH. From pooled literature-derived data, we performed Sensitivity/Specificity and simulation-based Receiver Operator Characteristic (ROC) analyses to estimate variable performance. Top-performing variables formed a PVOD/PCH Likelihood score, which had its accuracy tested for distinguishing histopathology-confirmed PVOD/PCH cases (n = 37) from PAH controls (n = 60) in three cohorts of transplant-eligible patients from the United States, Spain, and the Netherlands. MEASUREMENTS AND MAIN RESULTS: DLCO, six-minute walk desaturation, PaO2, sex, smoking history, CT septal line thickening, and CT lymphadenopathy had the highest sensitivity and specificity performance and were incorporated into the PVOD score. Across test cohorts, the score achieved a ROC area under the curve of 0.97 (95% CI 0.93-1.00) for discriminating PVOD/PCH and it retained accuracy when data were missing. CONCLUSIONS: This score could facilitate early PVOD/PCH identification in incident PAH, potentially helping expedite transplant referral and informing therapy initiation/titration decisions.
3. Remote Monitoring Approaches to Reduce Readmissions After Infection and Sepsis: A Randomized Clinical Trial.
Across 19 hospitals, four remote monitoring strategies after sepsis/lower respiratory infection did not improve 90-day days-at-home versus usual care; enrollment in RPM was 59.6% among assigned. In patients ≥65 years, RPM was inferior on days-at-home, arguing for careful targeting.
Impact: A pragmatic RCT challenges policy assumptions about universal post-discharge monitoring, especially in older adults, and informs reimbursement and service design.
Clinical Implications: Avoid routine RPM for all sepsis/LRTI discharges; consider targeted, patient-centered criteria and usability support, particularly for older adults. Do not delay escalation to proven interventions (e.g., timely clinic follow-up, home health) when RPM signals are ambiguous.
Key Findings
- No improvement in 90-day days-at-home with any RPM strategy versus usual care; CORs ranged 0.86–1.01.
- In patients ≥65 years, RPM arms had significantly fewer days-at-home (COR 0.56–0.67; high inferiority probabilities).
- RPM enrollment among those assigned was 59.6%, highlighting implementation and engagement challenges.
- Readmission proportions were similar across arms, not favoring RPM.
Methodological Strengths
- Multi-center, response-adaptive randomized trial with intention-to-treat analysis
- Bayesian framework estimating cumulative odds for days-at-home and prespecified subgroup analyses
Limitations
- Only 59.6% of those assigned to RPM enrolled, potentially diluting intervention effects
- Requiring smartphones/internet and single health system may limit generalizability; contamination across arms possible
Future Directions: Develop targeted RPM indications with user-centered design, age-aware workflows, and integration with proven transitional care; evaluate cost-effectiveness and heterogeneous treatment effects.
IMPORTANCE: The Centers for Medicare & Medicaid Services reimburses remote monitoring to reduce hospital readmissions, yet its effectiveness remains uncertain. OBJECTIVE: To evaluate effectiveness of remote monitoring in reducing readmissions following hospitalizations for serious infections overall and across prespecified subgroups. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted from March 25, 2021, to December 9, 2024, using response adaptive randomization among postdischarge patients with sepsis or lower respiratory tract infection across 19 hospitals. Eligible patients were 21 years or older, lived in western Pennsylvania, were insured through the UPMC Health Plan or traditional fee-for-service Medicare, had a smartphone or other internet-connected device, had no cognitive impairment, and were at moderate or high risk for readmission at index hospitalization admission based on an internal predictive model. Analyses were based on intention to treat; data were analyzed from April to June 2025. INTERVENTION: Four remote monitoring strategies combining questionnaire intensity (low vs high) and clinical response teams (standard vs enhanced) compared with usual care. MAIN OUTCOMES AND MEASURES: The primary end point consisted of days at home at 90 days after discharge, assessed by posterior probability distribution for the cumulative odds ratios (CORs) in each study arm compared with usual care. Secondary end points included mortality, readmission, functional status, quality of life, and use of emergency department and hospice services. RESULTS: Among the 1286 patients included in the analysis, the median age was 63 (IQR, 54-71) years; 665 patients (51.7%) were female. The median Charlson Comorbidity Index was 6 (IQR, 3-9), and 386 patients (32.6%) received intensive care. Patients were randomized to usual care (n = 399) or remote patient monitoring (RPM) with low- or high-intensity questionnaires and standard or enhanced clinical response team combinations: RPM-low standard response (n = 204), RPM-high standard response (n = 129), RPM-low enhanced response (n = 383), and RPM-high enhanced response (n = 171). Of 887 patients assigned to remote monitoring arms, 529 (59.6%) enrolled in the remote monitoring program. The median home days were similar across all study arms: 90 (IQR, 83-90) for usual care, 90 (IQR, 84-90) for RPM-low standard response, 90 (IQR, 85-90) for RPM-high standard response, 90 (IQR, 83-90) for RPM-low enhanced response, and 90 (IQR, 84-90) for RPM-high enhanced response. Compared with usual care, the CORs were 0.96 (credible interval [CrI], 0.70-1.32) for RPM-low standard response, 0.86 (95% CrI, 0.60-1.23) for RPM-high standard response, 1.01 (95% CrI, 0.76-1.33) for RPM-low enhanced response, and 0.96 (95% CrI, 0.69-1.36) for RPM-high enhanced response, and superiority probability was less than 55% for all comparisons. At least 1 readmission occurred in 151 of 399 patients (37.8%) in the usual care arm, 81 of 204 (39.7%) in the RPM-low standard response arm, 57 of 129 (44.2%) in the RPM-high standard response arm, 143 of 383 (37.3%) in the RPM-low enhanced response arm, and 62 of 171 (36.3%) in the RPM-high enhanced response arm. Among patients 65 years and older, standard and enhanced response arms had fewer home days compared with usual care (COR, 0.56 [95% CrI, 0.36-0.85] and 0.67 [95% CrI, 0.45-0.98], respectively; inferiority probability, 99.6% and 97.9%, respectively). CONCLUSIONS AND RELEVANCE: Among trial patients discharged after hospitalization for serious infections, remote monitoring did not increase time spent alive at home but reduced it in those 65 years and older. These findings support reevaluating and tailoring remote monitoring after acute care for sepsis and lower respiratory tract infection to support further alignment with patients' needs and desire for personalized monitoring. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04829188.